The Cambridge office of Goodwin is an important centre of excellence in the firm's international network, and it handles high-value M&A and investment transactions for companies in the technology and life sciences sectors. 'The team is well respected in the market and has extensive knowledge of VC, which means they deliver an excellent product and deal experience', remarks one client. Lead partners David Mardle, Malcolm Bates and Tim Worden are acknowledged experts in licensing, M&A, IP commercialisation, financing and regulatory matters. Up-and-coming partners Adam Thatcher and Elizabeth Rhodes also play key roles in VC and M&A transactions. Thatcher recently assisted shareholders of cloud email security platform Tessian Limited with its acquisition by Proofpoint Inc.
Testimonials
Collated independently by Legal 500 research team.
- ‘The team is well respected in the market and has extensive knowledge of VC, which means they deliver an excellent product and deal experience.’
‘Adam Thatcher has excellent experience on both company and investor side and is able to cut through key issues quickly. ’
‘The Goodwin corporate team in Cambridge are my firm's preferred corporate counsel on our venture capital investment and M&A transactions.’
‘Adam Thatcher, David Mardle and Elizabeth Rhodes are all highly regarded, with excellent incite into the venture capital market.’
‘Diverse team with truly collaborative approach to working.’
‘David Mardle is one of the leading VC lawyers in the UK and is vastly experienced in the VC sector. Elizabeth Rhodes offers a precise and detailed approach and is particularly impressive in negotiation of difficult points - she is assertive without being in nay way aggressive.’
‘I like the combo with the US Goodwin office, it is all under one roof, short communication lines. Excellent team members for our regional and global legal needs’
- 'The Goodwin corporate and commercial teams are exceptional. They are knowledgeable, responsive and commercial in their advice. I consider them to be true business partners.'
Key clients
- Tessian
- Citymapper
- Material Impact
- Dr Martens
- Pulsic
- Ophelos
- Chemify
- Oxford Quantum Circuits Limited
- CMR Surgical
- Gimv
- Cambridge Innovation Capital
- Panakes Partners
- Seroba Life Sciences
- Hadean Ventures
- Synaffix
- MiNA
- WuXi Biologics
- Renaissance Pharma Ltd.
- Tay Therapeutics
- Traverse Biotech
- Polpharma Biologics
- Stalicla
- Closed Loop Medicine
- Calypso Biotech
Work highlights
- Advised Synaffix on a number of licensing and collaboration agreements with MacroGenics Inc., ABL Bio, Inc. SOTIO Biotech and Innovent Biologics.
- Advised CMR Surgical on their recent US$165 million fundraising. The funding round was led by all of its major existing investors, including Ally Bridge Group, Cambridge Innovation Capital, Escala Capital, LGT and its affiliate impact investing platform Lightrock, RPMI Railpen, SoftBank Vision Fund 2, Tencent and Watrium.
- Advised Pulsic Limited on its acquisition by Cadence Design Systems, Inc. with an enterprise value of US$56.1 million.
Lawyers
Practice head
The lawyer(s) leading their teams.
Malcolm Bates, David Mardle, Tim Worden